"Our Technosphere platform we expect additional opportunities with partners as we're working on 10 different molecules here, some for Mannkind, some for partners, but we expect continued opportunities on Technosphere platform in the coming years."
Plus the FDA feedback. Type I & II pediatric approval would be a coup.